ClinVar Miner

Submissions for variant NM_002691.4(POLD1):c.883G>A (p.Val295Met)

gnomAD frequency: 0.00060  dbSNP: rs199545019
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000990252 SCV000287655 likely benign Colorectal cancer, susceptibility to, 10 2024-02-01 criteria provided, single submitter clinical testing
GeneDx RCV000236306 SCV000293151 uncertain significance not specified 2017-03-15 criteria provided, single submitter clinical testing This variant is denoted POLD1 c.883G>A at the cDNA level, p.Val295Met (V295M) at the protein level, and results in the change of a Valine to a Methionine (GTG>ATG). Bellido et al. (2015) identified this variant in two kindreds characterized by familial or early-onset mismatch repair proficient colorectal cancer and/or APC and MUTYH-negative polyposes. In one family POLD1 Val295Met was present in both a woman with early-onset colorectal cancer and her mother, who was diagnosed with colorectal cancer at age 70. In the second family, POLD1 Val296Met was observed in trans with a second POLD1 missense variant, Asp316Gly, which the authors interpreted as pathogenic. While the mother in this kindred, who was affected with breast and endometrial cancer, harbored both variants, a daughter affected with both colorectal and endometrial cancer only inherited POLD1 Asp316Gly. POLD1 Val295Met was not observed at a significant allele frequency in the NHLBI Exome Sequencing Project. Since Valine and Methionine share similar properties, this is considered a conservative amino acid substitution. POLD1 Val295Met occurs at a position that is conserved in mammals and is not located in a known functional domain (Tahirov 2009, Preston 2010). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether POLD1 Val295Met is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000509515 SCV000601960 benign not provided 2019-04-15 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV004529397 SCV000806567 likely benign POLD1-related disorder 2022-06-20 criteria provided, single submitter clinical testing This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Mendelics RCV000990252 SCV001141137 likely benign Colorectal cancer, susceptibility to, 10 2019-05-28 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000509515 SCV001152018 benign not provided 2023-10-01 criteria provided, single submitter clinical testing POLD1: BP4, BS1, BS2
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000236306 SCV001519529 likely benign not specified 2021-03-07 criteria provided, single submitter clinical testing Variant summary: POLD1 c.883G>A (p.Val295Met) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00055 in 218624 control chromosomes. The observed variant frequency is approximately 40 fold of the estimated maximal expected allele frequency for a pathogenic variant in POLD1 causing Colorectal Cancer phenotype (1.4e-05), strongly suggesting that the variant is benign. c.883G>A has been reported in the literature as a VUS in at-least two families with a history of cancers but no conclusive co-segregation with disease (example, Bellido_2016, Buchanan_2018) These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments some citing overlapping evidence utilized in the context of this evaluation (likely benign, n=2; benign, n=1; VUS, n=3). Based on the evidence outlined above, the variant was classified as likely benign.
Genetic Services Laboratory, University of Chicago RCV000236306 SCV002065987 likely benign not specified 2021-09-01 criteria provided, single submitter clinical testing DNA sequence analysis of the POLD1 gene demonstrated a sequence change, c.883G>A, in exon 8 that results in an amino acid change, p.Val295Met. This sequence change does not appear to have been previously described in patients with POLD1-related disorders and has been described in the gnomAD database with a population frequency of 0.14% in Ashkenazi Jewish subpopulation (dbSNP rs199545019). The p.Val295Met change affects a poorly conserved amino acid residue located in a domain of the POLD1 protein that is known to be functional. The p.Val295Met substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these evidences and the lack of functional studies, the clinical significance of the p.Val295Met change remains unknown at this time.
Sema4, Sema4 RCV002257546 SCV002534709 likely benign Hereditary cancer-predisposing syndrome 2021-01-27 criteria provided, single submitter curation
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV000236306 SCV002551891 uncertain significance not specified 2024-02-06 criteria provided, single submitter clinical testing
GenomeConnect, ClinGen RCV000509515 SCV000606987 not provided not provided no assertion provided phenotyping only GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001356392 SCV001551548 uncertain significance Carcinoma of colon no assertion criteria provided clinical testing The POLD1 p.Val295Met variant was identified in 2 of 1058 proband chromosomes (frequency: 0.002) from individuals or families with early-onset nonpolyposis CRC (Bellido 2016). The variant was also identified in dbSNP (ID: rs199545019) as "With Uncertain significance allele", and in ClinVar (classified as likely benign by Invitae; as uncertain significance by GeneDx and two clinical laboratories). The variant was identified in control databases in 120 of 243858 chromosomes at a frequency of 0.0005 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 9 of 5878 chromosomes (freq: 0.002), Latino in 35 of 30486 chromosomes (freq: 0.001), European in 52 of 109472 chromosomes (freq: 0.0005), Ashkenazi Jewish in 14 of 9360 chromosomes (freq: 0.002), and South Asian in 10 of 28292 chromosomes (freq: 0.0004); it was not observed in the African, East Asian, or Finnish populations. The p.Val295 residue is conserved in mammals but not in more distantly related organisms however computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and 2 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Clinical Genetics, Academic Medical Center RCV000509515 SCV001920022 likely benign not provided no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, University Medical Center Utrecht RCV000509515 SCV001931939 likely benign not provided no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000509515 SCV001953786 likely benign not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000509515 SCV001973450 likely benign not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.